An interventional study of Fresnel prism in Fresnel Prism, sponsored by Indonesia University. Completed at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Indonesia University · Not applicable, Interventional, and Treatment
Background: Homonymous hemianopia is a visual field defect that causes functional disabilities, such as decreased self-confidence, limited mobility, and increased risk of falls. Studies related to the effectiveness and comfort of Fresnel prisms, especially in the Indonesian population are limited.
Objective: To evaluate the effectiveness and comfort level of Fresnel prisms in expanding visual field in an Indonesian patient population with homonymous hemianopia.
: Fresnel prisms with a power of 40∆ were fitted to the patient's spectacles for two weeks. Visual field parameters were analysed using the Humphrey Field Analyzer with the SITA 24-2 algorithm, while the Pelli-Robson and ETDRS charts were used to assess contrast sensitivity and visual acuity, respectively. After visual assessment, comfort was quantitatively assessed using a comfort scale.
63 studies on the registry are indexed under Hemianopsia; 24 are open to participants now.
This study's enrollment of 25 is below the median of 32 across 53 interventional studies indexed under Hemianopsia.
Browse Hemianopsia studies →Indonesia University is the lead sponsor of 446 studies on the registry; 56 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Fresnel prism chosen was of 40∆ power (the largest size available) with the aim of the largest visual field expansion, which was 20 degrees that the patient felt during environmental orientation and mobilisation. Fresnel prism fitting was performed using the patient's spectacles (if wearing spectacles) or plano glasses provided by the researcher. The patient was then asked to practice scanning before being asked to wear the Fresnel prism for 5.5 hours daily for two weeks. Patients were given a wear sheet to evaluate the duration of wear in a day
Device: Fresnel prism
The Fresnel prism chosen was of 40∆ power (the largest size available) with the aim of the largest visual field expansion, which was 20 degrees that the patient felt during environmental orientation and mobilisation. Fresnel prism fitting was performed using the patient's spectacles (if wearing spectacles) or plano glasses provided by the researcher. The patient was given object movement stimulation to identify the visual field boundary and the Fresnel prism was placed 2 mm away from the healthy visual field area. The Fresnel prism was placed on the inner side of the lens. Vertical correction was performed in homonymous hemianopia depending on the visual field defect. The patient was then asked to practice scanning before being asked to wear the Fresnel prism for 5.5 hours daily for two weeks. Patients were given a wear sheet to evaluate the duration of wear in a day.
Visual Fied
Mean Deviation (dB) Pattern Standard deviation (dB) Visual field index (%)
Time frame: 2 weeks
TPDK
Sharp vision with correction (log mar)
Time frame: 2 weeks
Contrast sensitivity
Contrast sensitivity (log units)
Time frame: 2 weeks
Plan to share: No — IPD will not be shared due to patient privacy considerations
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.